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Background: There is scarce literature on the onset, progression and severity of cardiac hypertrophy and its effect on patient outcomes 
undergoing orthotopic heart transplantation (OHTx). We sought to identify any association between the development of cardiac allograft hypertrophy 
and incidence of cardiac allograft vasculopathy (CAV), biopsy-proven acute cellular rejection or long-term survival.
Methods: This was a retrospective study of adult OHTx patients from 2003-2010. After excluding those patients for whom serial echocardiographic 
reports were not available, a cohort of 241 patients was studied. Serial transthoracic echocardiograms and endomyocardial biopsies were collected 
with other demographic and clinical data. Left ventricular mass(LVM) was calculated as 0.8(1.04((LVDD+EDPWT+EDST)^3)-(LVDD^3))+0.6. Patients 
were classified as having severe (>225g) or normal (<=225g) LVM. CAV above ISHLT grade 2 was considered significant and development treated as 
a time to failure variable.
Results: Of our patient cohort, 20.75% developed severe LVM postoperatively. The mean age across all patients was 52.311.6 and with mean 
BMI of 25.75.0. Patients with severe LVM had significantly worse long-term survival left-censored at 1 year (p=0.016) when compared with normal 
patients. The severe group also experienced decreased freedom from CAV (p=0.02). Preoperative gender mismatch, female recipients, BMI were 
significant predictors (p<0.05) for development of severe LVM.
Conclusion: The prevalence of increased LVM in cardiac transplant recipients is highly associated with development of CAV and significantly 
affects long-term mortality. It is critical to consider independent predictors for the development of severe LVM, such as high BMI and donor-recipient 
gender mismatch when accepting organs. Meticulous screening for LVM and the introduction of appropriate management in its early stages may be 
helpful in reducing the development of CAV and long-term mortality amongst heart transplant recipients.
